Y
Yoko Kataoka
Publications - 18
Citations - 2196
Yoko Kataoka is an academic researcher. The author has contributed to research in topics: Atopic dermatitis & Medicine. The author has an hindex of 9, co-authored 12 publications receiving 1513 citations.
Papers
More filters
Journal ArticleDOI
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson,Thomas Bieber,Emma Guttman-Yassky,Lisa A. Beck,Andrew Blauvelt,Michael J. Cork,Jonathan I. Silverberg,Mette Deleuran,Yoko Kataoka,Jean-Philippe Lacour,Külli Kingo,Margitta Worm,Margitta Worm,Yves Poulin,Andreas Wollenberg,Yuhwen Soo,Neil M.H. Graham,Gianluca Pirozzi,Bolanle Akinlade,Heribert Staudinger,Vera Mastey,Laurent Eckert,Abhijit Gadkari,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +25 more
TL;DR: Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Journal ArticleDOI
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Thomas Bieber,Eric L. Simpson,Jonathan I. Silverberg,Diamant Thaçi,Carle Paul,Andrew Pink,Yoko Kataoka,Chia-Yu Chu,Marco DiBonaventura,Ricardo Rojo,Jeremias Antinew,Ileana A. Ionita,Rodney Sinclair,Seth Forman,Jacek Zdybski,Pinaki Biswas,Bimal Malhotra,Fan Zhang,Hernan Valdez +18 more
TL;DR: In this article, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleucin-13 signaling, was investigated for the treatment of atopic dermatitis.
Journal ArticleDOI
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
Joanne R Chalmers,Eric L. Simpson,Christian Apfelbacher,Kim S Thomas,L.B. von Kobyletzki,L.B. von Kobyletzki,Jochen Schmitt,Jasvinder A. Singh,Åke Svensson,Hywel C Williams,Katrina Abuabara,Valeria Aoki,Marius Ardeleanu,M. Awici-Rasmussen,Sébastien Barbarot,Teresa Løvold Berents,Teresa Løvold Berents,Joel A. Block,A. Bragg,T. Burton,K. K. Bjerring Clemmensen,A. Creswell-Melville,M. Dinesen,Aaron M. Drucker,Linda O. Eckert,Carsten Flohr,M. Garg,L.A.A. Gerbens,A. L. B. Graff,Jon M. Hanifin,Daniel Heinl,Rosemary Humphreys,H. A. Ishii,Yoko Kataoka,Yael Anne Leshem,B. Marquort,M. A. Massuel,S. Merhand,Hitoshi Mizutani,Hiroyuki Murota,Dedee F. Murrell,Takeshi Nakahara,I. Nasr,Kristine E. Nograles,Yukihiro Ohya,I. Osterloh,Jan Pander,C. A C Prinsen,L. Purkins,Matthew J Ridd,Tracey Sach,Marielouise Schuttelaar,S. Shindo,J. Smirnova,A. Sulzer,E. Synnove Gjerde,Roberto Takaoka,H. Vestby Talmo,Marie Tauber,F. Torchet,Annika Volke,Carl-Fredrik Wahlgren,Stephan Weidinger,Elke Weisshaar,Andreas Wollenberg,K. Yamaga,C. Y. Zhao,Ph.I. Spuls +67 more
TL;DR: This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V), held on 12–14 June 2017 in Nantes, France, with 81 participants to achieve consensus over the definition of the core domain of long‐term control and how to measure it.
Journal ArticleDOI
Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.
Hidehisa Saeki,Takeshi Nakahara,Akio Tanaka,Kenji Kabashima,Makoto Sugaya,Hiroyuki Murota,Tamotsu Ebihara,Yoko Kataoka,Michiko Aihara,Takafumi Etoh,Norito Katoh +10 more
TL;DR: The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity‐related patient outcomes with respect to several important points requiring decision‐making in clinical practice.
Journal ArticleDOI
Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis
TL;DR: Serum TARC is an extremely useful clinical biomarker for atopic dermatitis (AD) treatment and can be used for accurately monitoring proactive treatment for long‐term control and for improving patient adherence.